Longeveron, Inc. announced the initiation of its Phase IIa clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The Phase IIa trial is designed to measure brain anatomy using MRI, and include detailed assessments of the inflammatory and vascular systems thought to contribute to the worsening of AD.
[Longeveron, Inc.]
Sorry, but the selected Zotpress account can't be found.
